GENETIC SIGNATURES LIMITED
ASX:GSSPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 97.7% of what they think they own, once every option and right converts.
Runway 4–8 quarters
GENETIC SIGNATURES LIMITED's ordinary share count was 227M as of December 2024, up 0.1% since September 2024. The company had no capital raises in the past 24 months. Options and rights on issue could convert into 5M new shares, representing 2.4% of the current share count, with the nearest expiry in November 2035. The company reported A$19.2M in cash as of the June 2026 quarter, sufficient for approximately 5.5 quarters of funding. No proposed securities issues are currently pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 29 Mar 2026 | 3H · cancellation | GSS : ORDINARY FULLY PAID | 227.1M | Appendix 3H |
| 10 Feb 2026 | 3H · cancellation | GSS : ORDINARY FULLY PAID | 227.1M | Appendix 3H |
| 24 Nov 2025 | 3G · unquoted | GSS : ORDINARY FULLY PAID | 227.1M | Appendix 3G |
| 21 Nov 2025 | 3H · cancellation | GSS : ORDINARY FULLY PAID | 227.1M | Appendix 3H |
| 6 Nov 2025 | 3G · unquoted | GSS : ORDINARY FULLY PAID | 227.1M | Appendix 3G |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered4.6M · 2.0% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 4.1M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered834k · 0.4% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 479k priced, 5.0M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
An exercise price is on record for only 8.8% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.081 today. No price up to ten times today’s switches on any more priced supply.
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 5.0M (91.2% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
- 479k more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| GSSAC | Options | Price-triggered | $0.98 | 11 Nov 2035 | 479k | Filing |
| GSSAG | Performance rights | Condition-triggered | — | — | 334k | Filing Meeting |
| GSSAH | Rights | Condition-triggered | — | — | 500k | Filing Meeting |
| GSSAB | Options | Price-triggered | — | — | 4.1M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 24 Nov 2025 | Anne Lockwood | Other | 250k | — | — | — | 3Y notice |
| 24 Nov 2025 | Dr Jenny Harry | Other | 250k | — | — | — | 3Y notice |
| 6 Dec 2024 | Dr Neil Gunn | Other | — | 500k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.